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The meningococcal antigen typing system (MATS) sandwich enzyme-linked immunosorbent assay (ELISA) was designed to
measure the immunologic cross-reactivity and quantity of antigens in target strains of a pathogen. It was first used to measure
the factor H-binding protein (fHbp), neisserial adhesin A (NadA), and neisserial heparin-binding antigen (NHBA) content of
serogroup B meningococcal (MenB) isolates relative to a reference strain, or “relative potency” (RP). With the PorA genotype,
the RPs were then used to assess strain coverage by 4CMenB, a multicomponent MenB vaccine. In preliminary studies, MATS
accurately predicted killing in the serum bactericidal assay using human complement, an accepted correlate of protection for
meningococcal vaccines. A study across seven laboratories assessed the reproducibility of RPs for fHbp, NadA, and NHBA and
established qualification parameters for new laboratories. RPs were determined in replicate for 17 MenB reference strains at lab-
oratories A to G. The reproducibility of RPs among laboratories and against consensus values across laboratories was evaluated
using a mixed-model analysis of variance. Interlaboratory agreement was very good; the Pearson correlation coefficients, coeffi-
cients of accuracy, and concordance correlation coefficients exceeded 99%. The summary measures of reproducibility, expressed
as between-laboratory coefficients of variation, were 7.85% (fHbp), 16.51% (NadA), and 12.60% (NHBA). The overall within-
laboratory measures of variation adjusted for strain and laboratory were 19.8% (fHbp), 28.8% (NHBA), and 38.3% (NadA). The
MATS ELISA was successfully transferred to six laboratories, and a further laboratory was successfully qualified.
Serogroup B Neisseria meningitidis (MenB) is a worldwide pub-lic health threat that accounts for 90% of infant meningococ-
cal disease cases in many European countries (6, 13, 23, 26). Un-
like serogroups A, C, W-135, and Y, for which broad-coverage
polysaccharide protein conjugate vaccines are available, MenB has
presented unique challenges to vaccine development because its
polysaccharide capsule mimics the human neural cell adhesion
molecule (10). Therefore, various subcapsular targets have been
investigated since the 1980s (1, 5, 10, 15, 25).
To date, three licensed vaccines against invasive serogroup B
meningococcal disease based on wild-type outer membrane vesi-
cles (OMVs) have successfully contained clonal outbreaks in
Cuba, Norway, New Zealand, parts of Latin America, and Nor-
mandy, France (5, 15, 23, 26). However, these OMV vaccines do
not provide protection against strains carrying PorA serosubtypes
that differ from that in the vaccine (1, 5, 9, 15, 20, 21, 23, 25–27).
To provide protection against genetically diverse MenB strains,
several investigational vaccines, including formulations with mul-
tiple OMVs, recombinant OMVs, multiple PorA and FetA com-
ponents, or antigens discovered through genome mining, have
been developed (1, 5, 9, 10, 15, 20, 21, 23, 25–27). Of the several
investigational formulations that have entered the clinic, two vac-
cines that contain factor H-binding protein (fHbp), a novel pro-
tein antigen, have entered late-stage clinical trials (1, 25, 26). Ad-
ditional investigational MenB vaccines assessed in the clinic
include bi- and hexavalent PorA outer membrane vesicle (OMV)
vaccines (9, 20, 21, 23, 26, 27). However, only a single vaccine,
4CMenB, has completed phase 3 clinical trials and is under con-
sideration for licensure, while a bivalent fHbp vaccine has entered
late-stage clinical trials (1, 25). 4CMenB has four primary anti-
genic components: OMV from the New Zealand outbreak strain
NZ 98/254, fHbp, neisserial adhesin A (NadA), and neisserial hep-
arin-binding antigen (NHBA) (1, 2, 11, 23, 25).
Genotyping based on sequence variation of housekeeping
genes (multilocus sequence typing [MLST]) or surface-expressed
proteins such as PorA and FetA shows high genetic diversity
among meningococcal populations (16, 19). These patterns of
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variation do not account for additional surface proteins such as
the three recombinant antigens included in 4CMenB (2) because
of the high rates of recombination affecting the meningococcal
chromosome (4, 8). Moreover, MLST and antigen genotyping do
not account for expression levels or cross-reactivity to various
antigen variants present on pathogenic strains (3, 7, 19). To deter-
mine the potential impact of 4CMenB on endemic MenB bacteria
in different countries or regions, a new method was needed to
account for fHbp, NadA, and NHBA diversity and expression,
which varies among strains. The meningococcal antigen typing
system (MATS) was developed as a rapid, reliable system that
combines conventional genotyping for PorA with a specialized
sandwich enzyme-linked immunosorbent assay (ELISA) that de-
termines phenotypic expression and the cross-reactivity, or rela-
tive potency (RP), of fHbp, NadA, and NHBA on individual
strains (7).
MenB vaccine development requires the use of immunogenic
surface proteins, which can vary in sequence, and expression from
strain to strain, which can affect their ability to be targeted by
bactericidal antibodies (3, 7, 10, 15, 23). This dynamic profile
complicates the task of health authorities and recommending
agencies, which must assess whether circulating MenB strains are
susceptible to killing by a vaccine-induced immune response (5, 7,
13, 15, 23, 26). Conducting serum bactericidal assay using human
complement (hSBA), the accepted immunogenicity endpoint in
clinical trials of meningococcal vaccines, against large strain pan-
els to assess vaccine effects poses serious logistical and ethical chal-
lenges. To mitigate the need to perform hSBA on large panels of
isolates, the MATS method established a minimum level of RP,
named the positive bactericidal threshold (PBT) that predicts
whether a given MenB isolate would be susceptible to killing in
hSBA by antibodies induced by 4CMenB (6, 7).
MATS was developed as a reliable and reproducible means to
identify individual MenB strains likely to be covered by 4CMenB
(7). Obtaining a large body of current data on strain coverage will
be required to support national vaccine recommendations. More-
over, decentralizing such typing could accelerate these efforts and
provide a surveillance method to detect the potential emergence
of vaccine resistance over time. Given that many countries might
need this information, Novartis elected to transfer the MATS
ELISA to several national meningococcal reference laboratories.
To ensure that results would remain consistent and reproducible
wherever they were obtained and to determine criteria for validat-
ing additional laboratories, we performed the current interlabo-
ratory standardization study using a defined set of test strains.
Seven laboratories (A to G) used a standardized procedure for
MATS ELISAs and generated RPs for fHbp, NadA, and NHBA
that were subject to analysis based on a comprehensive statistical
plan.
MATERIALS AND METHODS
Bacterial strains used. MenB strains (see Table S1 in the supplemental
material) were obtained under materials transfer agreements from the
Norwegian Institute of Public Health (Oslo, Norway), the Health Protec-
tion Agency (Manchester, United Kingdom), and the Centers for Disease
Control and Prevention (Atlanta, GA). These strains were selected to pro-
vide examples of a range of MATS ELISA values and not as representative
of any particular country, region, or RP distribution.
MATS ELISA. To measure RPs for fHbp, NHBA, and NadA, ELISAs
were performed as described previously (23). Precoated microtiter plates,
antibody reagents, substrate buffer, washing buffer, and a written set of
instructions were provided in kit form by Novartis Vaccines & Diagnos-
tics. Briefly, bacteria were cultured overnight on chocolate agar (bioMéri-
eux) and then suspended in Mueller-Hinton broth (Difco) to a defined
optical density at 600 nm of 0.4. Empigen BB (Sigma) was added, and then
the bacterial suspensions were incubated for 1 h as described below for
inactivation by the lysis buffer. Serial dilutions of the bacterial lysate were
then transferred to microtiter plates previously coated with rabbit poly-
clonal antibodies specific for fHbp, NHBA, or NadA. The plates were
incubated and washed, and an antigen-specific secondary antibody, also
prepared in rabbits and labeled with biotin, was used to detect the bound
antigens. The plates were developed with streptavidin-horseradish perox-
idase and ortho-phenylene diamine substrate (Sigma), the reactions were
stopped with H2SO4, and the plates were read at 492 nm. The results were
analyzed with StatLIA (Brendan Technologies, Carlsbad, CA) by calculat-
ing the RP of the test strain bacterial lysate compared to that of a reference
strain that was treated identically and assayed in each microtiter plate
(H44/76 for fHbp, NGH38 for NHBA, and 5/99 for NadA).
In each laboratory, at least 12 assays considered acceptable, based on
visual evaluation of the dilution curves, were used to constitute a reference
data set used by StatLIA to determine mean-variance regressions and
typical variability of the standard curve. On this basis, a weighted five-
parameter logistic regression was performed for the optical densities of
the test samples and of the reference samples of each assay, and the RP was
determined by parallelism analysis of the regressions for the test and the
reference strain (14, 18). For all laboratories, acceptance criteria previ-
ously defined and based on StatLIA P values (7) were used to determine
acceptability of each microtiter plate and individual test strain. The fol-
lowing laboratories participated in the study: the Division of Bacterial
Diseases, Centers for Disease Control and Prevention (Atlanta, GA); No-
vartis Vaccines & Diagnostics (Siena, Italy); the National Reference Cen-
tre for Meningococci, IBI Unit, Institut Pasteur (Paris, France), the Ref-
erence Laboratory for Meningococci, Institute of Health Carlos III
(Madrid, Spain), the National Reference Laboratory for Meningococci,
University of Würzburg, Institute for Hygiene and Microbiology (Würz-
burg, Germany), the Manchester Laboratory of the Health Protection
Agency (Manchester, United Kingdom), the Department of Infectious
Diseases, Istituto Superiore di Sanità (Rome, Italy), and the Department
of Bacteriology and Immunology, Norwegian Institute of Public Health
(Oslo, Norway). Laboratories participating to the standardization study
were randomly designated A to G. A laboratory that performed the qual-
ification study was designated H.
Study design. Seven laboratories (A to G) performed multiple MATS
ELISAs for fHbp, NHBA, and NadA on 17 shared strains (Table 1; see also
Table S1 in the supplemental material).
We previously (7) defined provisional lower limits of quantitation
(LLOQs) for fHbp, NadA, and NHBA based on data from one laboratory.
TABLE 1 Laboratories A to G participating in the interlaboratory study
and the number of strains assayed at two temperatures for bacterial
lysate preparation
Laboratory
No. of strainsa
fHbp NHBA NadA
37°C 45°C 37°C 45°C 37°C 45°C
A 10 (10) 2 (2) 17 (17) 6 (6) 8 (8) 3 (3)
B 13 (10) 3 (2) 17 (17) 6 (6) 8 (8) 3 (3)
C 17 (10) 12 (10) 17 (17) 17 (17) 10 (9) 7 (7)
D 16 (10) 1 (1) 17 (17) 6 (6) 8 (8) 2 (2)
E 10 (10) 2 (2) 17 (17) 6 (6) 8 (8) 2 (2)
F 17 (10) 0 (0) 16 (16) 0 (0) 8 (8) 0 (0)
G 0 (0) 15 (11) 0 (0) 17 (17) 0 (0) 13 (11)
a The numbers of strains with assayed values above LLOQ that define the core of
reference MATS isolates appear in parentheses. The lysate preparation temperatures are
indicated in the column subheadings.
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In the present study, analysis of variance (ANOVA) models using data
from laboratories A to G were used to redefine these limits as 0.009, 0.04,
and 0.0009 for fHbp, NHBA, and NadA, respectively. RP values less than
these were excluded from the present analysis.
During the present study, antigen extraction at 37°C (room temperature)
permitted the survival of small numbers of bacteria at some laboratories,
which could potentially pose a safety risk for laboratory workers. Retesting
revealed that antigen extraction at 45°C for 1 h resulted in complete inactiva-
tion of bacterial suspensions for all laboratories. Therefore, the temperature
for bacterial lysate preparation was changed to 45°C. Five laboratories assayed
strains at both temperatures to determine possible effects on RP values. Lab-
oratory G used 45°C, and laboratory F used 37°C only (Table 1).
Construction of a core of reference MATS strains. RPs below the
LLOQ were excluded from all analyses. For fHbp and NadA, all replicate RPs
for several strains were below the LLOQ, leaving core sets of 10 (fHbp), 17
(NHBA), and 8 (NadA) strains (see Fig. 1A, B, and C, respectively).
Statistical analysis. RPs were log10 transformed prior to analysis. For
the 17 test strains, consensus RP values were estimated across the labora-
tories A to G, using an ANOVA mixed-effects model. Consensus RPs were
then used to quantify accuracy, reproducibility, repeatability, precision,
and bias within and among the laboratories. Accuracy, defined as the
closeness of a laboratory-assayed value to the consensus value, was mea-
sured using Lin’s coefficient of accuracy (Ca) (25). Precision, a measure of
how far a set of observations deviate from a fitted straight line, was quan-
tified using Pearson correlation coefficient (r). Lin’s concordance corre-
lation coefficient (rc), a combination of Ca and r, was used to form a single
statistic describing accuracy and precision. Repeatability, a measure of
intralaboratory variation (for replicate assays), and reproducibility, a
measure of interlaboratory variation (an estimate of the overall error) of
the assay, were expressed as coefficients of variation (CVs). Bias is a mea-
sure of directional error (consistent offset) of the laboratory titer com-
pared to the consensus RP (26).
Linear mixed-effects ANOVA models were used to estimate consensus
values for each strain and antigen, as well as assay repeatability and reproduc-
ibility. All models were fit independently by antigen and included strain and
laboratory as random effects. Since each strain was assayed in replicate, a
single predicted RP was estimated using the ANOVA models to represent the
replicate values for analysis and comparison of laboratories in the figures and
tables. Prediction intervals used to develop acceptance criteria for future lab-
oratories were also derived from these ANOVA models.
The estimated values from the ANOVA models were used to assess and
evaluate the ability of laboratories A to G to reproduce RPs and to test the
consistency of the RPs with consensus values. Laboratory bias was quan-
tified by comparing observed laboratory values to consensus values. For
each individual antigen, the mean bias was expected to be zero.
Development of qualification criteria for new laboratories. Antici-
pating the need for additional laboratories to use the MATS ELISA, the
present data were used to suggest qualification criteria. A protocol was
then set up to ensure that new laboratories produced results within toler-
ance limits defined by the variability measured in the present study. This
approach also would ensure that new laboratories developed adequate
proficiency to qualify to use the MATS ELISA. A laboratory that met these
specifications would be considered qualified to assay new strains, and the
resulting RPs would be considered consistent with those measured by
laboratories A to G.
RESULTS
MATS strains span a wide assay range. Figure 1 displays the dis-
tribution of RPs for each strain and antigen. Each box represents
FIG 1 Reference MATS strains and robustness of positive bactericidal thresh-
olds (PBTs) for fHbp (A), NHBA (B), and NadA (C). Box plots show the
median and interquartile ranges of RPs collected during the present study,
combined over laboratories A to G. Vertical lines extend to the most extreme
observation that is 1.5  the interquartile distance (75th to 25th percentiles).
Each box represents all replicate assay data for each strain and antigen com-
bined over all laboratories. Dashed and solid horizontal lines indicate PBT and
95% CIs derived according to equation 1.
Interlaboratory Standardization of MATS ELISA
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all replicate assay data for each strain and antigen combined over
all laboratories.
MATS RPs were robust in response to temperature change
during lysate preparation. ANOVA models were constructed ad-
justing for laboratory (A to G), antigen, as well as lysate prepara-
tion temperature, from the replicate RPs submitted for analysis.
For the five laboratories that assayed the strains at both tempera-
tures, the predicted RPs were derived for each laboratory, strain,
antigen, and temperature combination, yielding 75 pairs of mea-
surements that are plotted in Fig. 2. In this scatter plot, the line of
identity represents perfect agreement (intercept  0, slope  1).
Agreement was generally excellent, with data clustered tightly over
the line of identity. Lin’s coefficient of accuracy (Ca) was 0.999
(95% confidence interval [CI]  0.997 to 1.00). Precision was
high; the Pearson correlation coefficient was 0.993 (95% CI 
0.988 to 0.995), and the combined concordance correlation coef-
ficient (rc) was 0.992 (95% CI  0.987 to 0.995). Due to this high
level of agreement, we combined results at 37 and 45°C for all
remaining analyses.
Interlaboratory correlations of MATS RPs were close to
identity. ANOVA models were used to estimate single RPs for
each strain by laboratory and antigen. Scatter plots comparing
these predicted RPs among laboratories A to G and combined over
the three antigens are shown in Fig. 3. Most lab-to-lab compari-
sons yielded clusters of points centered over the line of identity
(which represents perfect agreement), indicating good agreement
between laboratories A to G. Table 2 presents a comparison of RPs
among laboratories A to G for accuracy (Ca), precision (Pearson
r), and concordance correlation coefficient (rc), combined over
the three antigens. Accuracy, precision, and concordance were all
high and exceeded 0.99. The RPs for laboratory A were slightly
higher than those for laboratories B to G, as indicated by the small
upward shift in the point clusters in Fig. 3; however, no significant
impact on the quality of the interlaboratory correlations, whose
95% lower confidence bounds (LCB) remained 0.984, was de-
tected (Table 2).
MATS repeatability supports the within-laboratory discrim-
inatory power for RPs. ANOVA models were used to estimate
consensus RPs for each antigen and strain. Box plots displaying
the distribution of the fold differences between the individual lab-
oratory-reported and consensus RPs by antigen are shown by an-
tigen in Fig. 4A. The total span of the box plot, including the
vertical lines above and below the interquartile range, is a direct
indicator of within-laboratory variability (repeatability, see Table
S2 in the supplemental material for variances and CVs). For ex-
ample, boxes centered about the gray dashed line in Fig. 4 (which
represents the consensus value) with vertical lines extending be-
tween 1/2 and 2 indicate an experimental distribution of RPs
within a 2-fold difference from the consensus value. The exper-
imental ranges of the assay from LLOQ to the maximum observed
RP were 200-, 50-, and 2,000-fold for fHbp, NHBA, and NadA,
respectively The largest within-laboratory variability (or worst re-
peatability) for NHBA was observed in laboratory F, which had
a 2.3-fold difference between the two ends of the vertical lines of
the box. The 50-fold experimental range for NHBA can be subdi-
vided in 11 nonoverlapping 4.6-fold ranges from LLOQ to the
maximum RP observed, which represent the minimum discrimi-
natory power of a standardized laboratory for NHBA-RPs. For
fHbp and NadA, which each had a wider experimental range, a
better within-lab discriminatory power can be calculated in the
same way. A quantitative measure of within-laboratory CVs by
antigen and adjusted for strain is shown in Fig. 4B. For laborato-
ries A to G, fHbp displayed the lowest degree of within-laboratory
variance, NHBA showed an intermediate level of variance, and
NadA had the highest degree of variance, although laboratory F
reported a slightly higher CV for NHBA than for NadA.
MATS RPs are not affected by a systematic bias. Within-lab-
oratory bias per antigen was also estimated from the ANOVA
models, as illustrated in Fig. 4A by the distance of the mean (*)
from the gray dashed line at 1, for each laboratory (A to G) and
antigen (FHbp, NadA, and NHBA). The mean bias varied across
antigens and laboratories and did not display any systematic pat-
terns or associations between bias and variability. For example,
laboratory A had substantial positive bias and high variability for
NadA, positive bias and lower variability for NHBA, and virtually
no bias and low variability for fHbp. Conversely, laboratory F had
FIG 2 Comparison RPs at two temperatures for bacterial lysate preparation. For the five laboratories (A to E) that assayed the strains at both temperatures, the
predicted RPs were derived for each laboratory, strain, antigen, and temperature combination (n  75 pairs). The line of identity represents perfect agreement
(intercept  0, slope  1).
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negative bias and high variability for NadA, no bias and high vari-
ability for NHBA, and positive bias and low variability for fHbp.
Between-laboratory variation had only a minor impact on
MATS RPs. In Fig. 4A, the relative positioning of the boxes about
the gray dashed line for a given antigen across laboratories A to G
gives a visual indication of the between-laboratory variability. Ta-
ble S2 in the supplemental material lists the between-laboratory
CVs for each antigen. Table S2 also tabulates the within-labora-
tory CV for each lab and antigen. Finally, Table S2 lists the overall
within-laboratory CV for each antigen adjusted for laboratory and
strain. The within-strain CV is plotted opposite the predicted RPs
in Fig. 4C. This plot provides the opportunity to observe whether
there is a relationship between variability and the magnitude of
the RP. In general, samples with the lowest RP values exhibited the
greatest degree of within-strain variability.
Between-laboratory CVs for each antigen were 7.85% (fHbp),
12.60% (NHBA), and 16.51% (NadA). Overall, the within-labo-
ratory CVs estimated from ANOVA models adjusted for strain
and laboratory were 19.8, 28.8, and 38.3% for fHbp, NHBA, and
NadA, respectively. The between-laboratory CVs were lower than
the within-laboratory CVs for each of the three antigens. This
indicates that intrinsic biological variables such as bacterial
growth contributed more to the overall variability of the assay
than did differences between the laboratories.
Interlaboratory-derived 95% CIs for the PBT provided ro-
bust vaccine strain coverage predictions. As previously de-
scribed, any strain with an RP above the PBT for any antigen is
predicted to be covered by 4CMenB (23). To assess the 95% CIs of
strain coverage, a sufficient number of replicate assays for each
strain could be performed to estimate the 95% CI values for the RP
of each strain to be compared to the PBT; however, this strategy is
not feasible with large panels of strains. Alternatively, the 95% CI
for the PBT could be used to assess coverage with 95% confidence
for single RPs from individual strains. Using data from the present
study, we derived an empirical estimate of the 95% CI around the
PBT as follows:
PBT 95% CI  10^[log10(PBT)  1.96 · ] (1)
Since the PBT is strain independent, in equation 1 we used the
overall within-laboratory variances 2 for fHbp, NadA, and
NHBA adjusted for strain and laboratory as estimated by our
ANOVA models described above (see Table S2 in the supplemen-
tal material). The 95% CIs of the PBT obtained for fHbp (0.014 to
0.031, point estimate  0.021), NadA (0.004 to 0.019, point esti-
mate  0.009), and NHBA (0.169 to 0.511, point estimate 
0.294) are shown in Fig. 1.
We propose using the PBT 95% CIs to define empirical limits
to predict strain coverage by 4CMenB. Comparing individual RPs
from tested strains to the PBT 95% CI bounds will account for
boundaries around the estimate of strain coverage, defined in
terms of both within- and between-laboratory variances. If the
number of strains used to generate the estimate is significantly
smaller than the population of strains for which vaccine strain
coverage is being estimated, then additional corrections may be
needed.
One possible limitation of the PBT 95% CI bounds is that
among replicate RPs from a single strain some could be both
above and below these bounds, which would indicate that the
strain is simultaneously covered and not covered and thereby in-
validate the model. To confirm that the PBT 95% CI bounds pro-
vide a robust measurement for strain coverage, we examined the
empirical distribution of experimental RPs at or above the LLOQ
FIG 3 Scatter plots of pairwise comparisons of RP values derived from ANOVA models, adjusting for laboratory (A to G), antigen, and lysate preparation
temperature, from the replicate RPs submitted for analysis. The data are combined over antigens and plotted on a log10 scale. Predicted RPs were derived from
ANOVA random-effects models. The number of strains in common between any two laboratories is listed in Table 2. The solid line indicates perfect agreement
(intercept  0, slope  1).
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for all laboratories and strains tested, as shown in Fig. 1. No strain
had replicate RPs that were both above the 95% upper confidence
bound (UCB) and below the 95% LCB, either within or across
laboratories, indicating that the empirical PBT 95% CI is robust
and capable of accounting for within-laboratory and between-
laboratory variation.
Qualification guidelines for new laboratories. Based on our
results, we propose the following criteria be used to qualify a lab-
oratory to perform the MATS ELISA to assess 4CMenB. (i) Use the
12 quality-control strains defined in Table S3 in the supplemental
material, spanning the range of RPs for fHbp (8/12 strains),
NHBA (12/12 strains), and NadA (6/12 strains). (ii) Collect a min-
imum of 12 assays (microtiter plates) per antigen that have been
deemed reasonable by visual evaluation of the reference dilution
curves and then build a reference data set and analyze the assays in
StatLIA. (iii) Retest test strains that fail StatLIA acceptance criteria
(7) to collect a minimum of five acceptable results above the
LLOQ per strain, per antigen for those with positive results. (iv)
For fHbp, NadA, and NHBA, ensure that all strains display a geo-
metric mean of RPs within the range reported in Table S3 in the
supplemental material, and a CV equal to or lower than the max-
imum CV reported in Table S3. For failures, identify and solve the
source of the problem, and repeat the test. A deviation in one of
these criteria by a small amount for a single strain per antigen is
acceptable. (v) Finally, for fHbp, NadA, and NHBA, ensure that at
least 95% of the RPs are within the 95% prediction intervals re-
ported in Table S3 and also that at most one RP per strain falls
outside the 95% prediction intervals. For any failures, identify and
solve the source of the problem and then repeat the testing for the
failed strains starting with those having the largest deviation from
predicted values until both criteria are met.
These proposed laboratory qualification criteria were tested
using laboratory H. Figure S1 in the supplemental material shows
the distribution of geometric means, CVs, and assay values relative
to the range of geometric means, of CVs and to the 95% prediction
intervals listed in Table S3 in the supplemental material. The RPs
produced in laboratory H were consistent with those produced in
the standardized laboratories and qualify laboratory H to perform
TABLE 2 RP comparison between laboratories for accuracy, precision, and concordance correlation coefficient combined over antigens for
laboratories A to Ga
Laboratory Statistic
Laboratory
B C D E F G
A n 35 35 35 35 34 35
Accuracy (Ca) 0.995 0.997 0.996 0.996 0.999 0.999
Precision (r) 0.997 0.999 0.995 0.998 0.997 0.997
CCC (rc) 0.992 0.996 0.991 0.995 0.996 0.995
95% CI 0.986–0.996 0.993–0.998 0.984–0.995 0.99–0.997 0.992–0.998 0.991–0.998
B n 35 35 35 34 35
Accuracy (Ca) 0.999 1 1 0.998 0.999
Precision (r) 0.998 1 1 0.998 1
CCC (rc) 0.998 1 1 0.996 0.999
95% CI 0.996–0.999 0.999–1 1–1 0.993–0.998 0.998–0.999
C n 35 35 34 35
Accuracy (Ca) 0.999 1 0.999 0.999
Precision (r) 0.997 0.999 0.999 0.998
CCC (rc) 0.996 0.999 0.999 0.997
95% CI 0.993–0.998 0.997–0.999 0.998–0.999 0.995–0.999
D n 35 34 35
Accuracy (Ca) 1 0.998 0.999
Precision (r) 0.999 0.998 1
CCC (rc) 0.999 0.996 0.999
95% CI 0.998–1 0.993–0.998 0.999–1
E n 34 35
Accuracy (Ca) 0.999 0.999
Precision (r) 0.998 1
CCC (rc) 0.997 0.999
95% CI 0.995–0.998 0.999–1
F n 34
Accuracy (Ca) 0.999
Precision (r) 0.999
CCC (rc) 0.998
95% CI 0.996–0.999
a Relative potency (RP) comparisons between laboratories for accuracy (Ca), precision (Pearson’s r), and concordance correlation coefficient (rc) combined over antigens for
laboratories A to G are shown. The predicted RPs were obtained for laboratories A to G by sample within an antigen for each series of replicate values using random-effects ANOVA
models. n represents the number of strains in common over the three antigens with a maximum of 35 (10 fHbp  17 NHBA  8 NadA).
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the MATS ELISA and therefore to use the MATS method to assess
strain coverage by 4CMenB. As additional laboratories provide
data, refinements may be made to the proposed qualification cri-
teria.
DISCUSSION
Statistical methodologies used in this investigation have been ap-
plied previously in similar studies. In characterizing a new human
pneumococcal standard reference serum, Goldblatt et al. (12) per-
formed a study bridging the new reference sera (007sp) with the
one in current use (89SF). Five laboratories performed the WHO
reference pneumococcal ELISAs on a panel of 12 WHO calibra-
tion sera for 13 pneumococcal serotypes. Kapasi et al. (17) en-
rolled four laboratories to perform a comparative study of four
different sources of pertussis toxin (PT) in an IgG anti-PT ELISA.
Rose et al. (22) examined the level of agreement among six labo-
ratories measuring antibody-mediated killing of Streptococcus
pneumoniae (pneumococcus) by phagocytes using each laborato-
ry’s own optimized opsonophagocytic assay (OPA) on a panel of
16 WHO calibration reference sera for 13 pneumococcal sero-
types. In previous studies (12, 22), concordance correlation results
were very good since the laboratory-to-laboratory rc values ex-
ceeded 0.96 and 0.97, respectively, among all laboratories. In the
study by Kapasi et al. (17), due to the lack of assay standardization
and the inherent variability of OPA, concordance was somewhat
reduced: laboratory-to-laboratory rc values ranged from 0.67 to
0.99 for all six laboratories with five of the six laboratories exhib-
iting an rc of 0.80.
The laboratory-to-laboratory rc values measured during the
present interlaboratory standardization of the MATS ELISA ex-
ceeded 0.99 for all labs, indicating an excellent agreement within
and across all participating laboratories for all three antigens,
which was equal to or higher than that observed in the similar
studies mentioned above.
Of note, no predefined gold-standard RP values were used for
the MenB strains examined in this study, and the ANOVA mixed
model provided a mechanism for estimating consensus values that
served as assigned values for each strain for the duration of the
study. The choice to use a consensus value rather than establishing
a definitive RP in the laboratory where MATS was initially devel-
oped reflects the desire to develop a real-world assay whose stan-
dardization and qualification criteria are co-owned by the labora-
tories that perform it.
Mixed-model analysis of variance allowed us to partition the
total variance to measure reproducibility and repeatability. The
within-laboratory variation was 2 to 2.5 times higher than the be-
tween-laboratory variation for each antigen, indicating a very
good level of assay standardization across laboratories but also a
significant level of intrinsic variability in the assay. Within-strain
CVs measured for each antigen show that variability is slightly
increased for low RPs and that CVs varied significantly from strain
to strain, but also that, for each antigen, the less variable strain had
a CV higher than the between-laboratory CV. Taken together,
these results suggest that, even though strain-specific characteris-
tics and the biochemistry of the assay at low concentrations may
have an impact on MATS variability, a major source of assay vari-
ation is intrinsic to the experimental procedure and may be asso-
ciated with the quantification of the bacterial suspension that is
processed in the assay due to the biological variability of bacterial
growth.
One interesting and unanticipated finding observed here was
that a small number of bacteria survived Empigen lysis at room
temperature in some collaborating laboratories. Exposure to live
meningococci is an unacceptable health risk to laboratory work-
ers; therefore, the lysate preparation temperature was adjusted to
ensure the safety of MATS operators. This effect is probably strain
dependent and indicates that safety precautions need to be evalu-
ated for larger panels of meningococcal strains. Subsequent anal-
ysis showed that changing the lysate preparation temperature to
45°C had no significant effect on RPs and supported combining
data from all of the assays in this study.
One important goal of the present study was to provide addi-
tional national laboratories with an opportunity to obtain the
MATS ELISA without additional interlaboratory studies. There-
fore, a set of qualification criteria were established to permit a
laboratory to test its proficiency in MATS relative to the laborato-
ries (A to G) standardized here. A volunteer national laboratory
(laboratory H) followed the qualification procedure and obtained
MATS ELISA results that were highly consistent with those in the
seven standardized laboratories. As additional laboratories con-
tinue to provide assay data, the qualification criteria presented
here may be refined.
Strain coverage is a critical component in estimating the po-
tential clinical effects of vaccines against MenB, a pathogen char-
acterized by dynamic mutability and strain epidemiology, as well
as a propensity among its more virulent encapsulated strains to
cause prolonged epidemic disease. Due to this diversity, the
amount of serum required for testing using the existing correlate
of protection, the hSBA, is prohibitively high, particularly in trials
of infants. In a previous study (7), a minimum MATS RP, the PBT,
was established to indicate that a given MenB strain was suscepti-
ble to killing in the SBA by antibodies induced by 4CMenB. In the
present study, a heuristic method based on interlaboratory varia-
tion was developed to derive 95% CIs for strain coverage esti-
mates. The results presented here demonstrate that the MATS RPs
produced in each standardized or qualified laboratory can be
compared to the PBTs defined in one of the participating labora-
tories to obtain estimates of vaccine strain coverage that are con-
sistent among them, within the 95% intervals defined.
The PBTs used to define vaccine strain coverage were derived
by comparing MATS to pooled hSBA titers on a panel of 57 MenB
strains. The use of a broader strain panel and comparison to hSBA
data from individual subjects may further support the use of
FIG 4 (A) Box plots by antigen and laboratory (A to G) for the fold difference between the consensus and observed RPs. Consensus RPs were estimated for each
strain and antigen using a random-effects ANOVA model. The box is defined by the 25th and 75th percentiles of the distribution; the horizontal line in the box
represents the median (50th percentile) and the asterisks (*) signify the means. Vertical lines extend to the most extreme observation that is 1.5  the
interquartile distance (75th to 25th percentiles). Diamonds and small boxes (, ) correspond to moderate and severe outlying assay values, respectively. Each
box represents the distribution of all replicate data for all strains within a laboratory and antigen. (B) Plots of within-laboratory CVs by antigen derived using
random-effects ANOVA models. (C) Plots of within-strain CVs by antigen using random-effects ANOVA models. For fHbp, NadA, and NHBA, the strains are
plotted on the x axis using consensus RPs derived from ANOVA models.
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MATS to assess MenB strain coverage independent of clinical sera.
This might allow clinical trials to predict vaccine efficacy using a
limited number of strains. In addition, the extremely good agree-
ment observed here among different laboratories suggests that the
technology adopted in the MATS ELISA could be successfully
used to perform similar testing with different antigens or patho-
gens, providing a general platform for bacterial antigen pheno-
typing.
A possible area for future investigation with MATS is as a
means of postimplementation surveillance of the genetic profiles
of fHbp, NadA, and NHBA on circulating meningococcal strains,
allowing reference laboratories to monitor the antigenic profiles
of pathogenic isolates in real time (24). In addition, MATS might
be used to assess the actual nature of potential vaccine failures,
which has added importance for outer membrane protein vac-
cines against MenB, given that not all circulating strains will nec-
essarily be covered. Postimplementation surveillance data based
on a standardized assay could allow an indirect comparison of
immunization policies across countries and regions, providing a
valuable basis for rapid adaptation of public health policies based
on worldwide quantitative data.
In summary, the results reported indicate that MATS is a stan-
dardized, reproducible antigen typing system that robustly pre-
dicts 4CMenB strain coverage in different geographical regions.
These results suggest that MATS may have utility in epidemiologic
surveillance of meningococci and could be adapted for assessing
other pathogens.
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